Impact of stress hyperglycemia ratio on mortality in patients with critical acute myocardial infarction: insight from american MIMIC-IV and the chinese Cardiorenal ImprovemeNt II (CIN-II) study
Authors' conclusion
Among critical AMI patients, elevated SHR is significantly associated with and 1-year and long-term all-cause mortality, especially in those without diabetes, and the results are consistently in both American and Chinese cohorts.
Study context
- Population
- Critical acute myocardial infarction (AMI) patients with first intensive care unit (ICU) admission, American MIMIC-IV and Chinese CIN-II cohortsAmerican MIMIC-IV 2,166 · Chinese CIN-II 2,171
- Participants
- 4,337 patients2 cohorts
- Exposure
- Stress hyperglycemia ratio (SHR) quartiles
- Outcome
- All-cause mortality
- Follow-up
- 1-year and long-term
Methodological detailstwo cohorts: MIMIC-IV database and multicenter registry CIN-II
- Two cohorts: MIMIC-IV database and multicenter registry CIN-II
Main finding
As reported in the abstract
All-cause mortality, MIMIC-IV
Estimate (95% CI)
Quartile 4vs Quartile 2
aHR (1-year) 1.87(1.40–2.50)
Quartile 4vs Quartile 2
aHR (long-term) 1.63(1.27–2.09)
- Total mortality, MIMIC-IV (max follow-up 12.1 years)
- 23.8%
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| All-cause mortality, CIN-II · 1-year and long-termQuartile 4vs Quartile 2 | aHR (1-year) 1.44 (95% CI 1.03–2.02) | |
| All-cause mortality, CIN-II · 1-year and long-termQuartile 4vs Quartile 2 | aHR (long-term) 1.32 (95% CI 1.05–1.66) | |
| 0.512Ratio (log scale) |
- All-cause mortality, CIN-II — Total mortality, CIN-II (max follow-up 14.1 years)
- 29.1%
Subgroup: patients without diabetes · 1-year and long-term
- SHR significantly associated with higher all-cause mortality in patients without diabetes, both cohorts
Original publication
Impact of stress hyperglycemia ratio on mortality in patients with critical acute myocardial infarction: insight from american MIMIC-IV and the chinese CIN-II study. Cardiovasc Diabetol. Published 21 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →